PUMA2A
Based on 1 Customer Validation
PUMA2A is a PUMA BH3-only peptide. PUMA2A can be used as a negative control in Cytochrome C release assays and BH3 profiling. PUMA2A can be used in the research of chronic myeloid leukemia.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.46%
- Formule: C96H156N34O30S
- Masse moléculaire:2298.54
-
Stockage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
In Vitro
PUMA-2A (1-100 μM; 2 h) does not induce significant mitochondrial membrane potential loss in K562 CML cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Appearance Solid
-
Masse moléculaire 2298.54
-
Formule C96H156N34O30S
-
Color White to off-white
-
Sequence
Ac-Glu-Gln-Trp-Ala-Arg-Glu-Ile-Gly-Ala-Gln-Ala-Arg-Arg-Met-Ala-Ala-Asp-Leu-Asn-Ala-NH2
-
Sequence Shortening
Ac-EQWAREIGAQARRMAADLNA-NH2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvant et solubilité
In Vitro:
DMSO : 1 mg/mL (0.44 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[2]. Lucas CM, et al. High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia. Leukemia. 2016;30(6):1273-1281. [Content Brief]
[3]. Butterworth M, et al. BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells. Br J Cancer. 2016;114(6):638-641. [Content Brief]
[4]. Alhuthali HM, et al. The natural alkaloid Jerantinine B has activity in acute myeloid leukemia cells through a mechanism involving c-Jun. BMC Cancer. 2020;20(1):629. Published 2020 Jul 7. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PUMA2A Related Classifications
HY-P11705 Related Classifications
Powered by Bioz